6-(4-(2,2-Di(4-Fluorophenyl)ethylamino)-1-piperidinyl)-N,N-di-2-propenyl-1,3,5-triazine-2,4-diamine (BioDeep_00000841835)
代谢物信息卡片
化学式: C28H33F2N7 (505.2765362)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C=CCNC1=NC(=NC(=N1)N2CCC(CC2)NCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)NCC=C
InChI: InChI=1S/C28H33F2N7/c1-3-15-31-26-34-27(32-16-4-2)36-28(35-26)37-17-13-24(14-18-37)33-19-25(20-5-9-22(29)10-6-20)21-7-11-23(30)12-8-21/h3-12,24-25,33H,1-2,13-19H2,(H2,31,32,34,35,36)
描述信息
D000970 - Antineoplastic Agents
同义名列表
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Grégoire Dirson, Christine Fernandez, Patrick Hindlet, Françoise Roux, Michèle German-Fattal, François Gimenez, Robert Farinotti. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
Pharmaceutical research.
2006 Jul; 23(7):1525-32. doi:
10.1007/s11095-006-0279-5. [PMID: 16779703] - Andrew Collett, Jolanta Tanianis-Hughes, David Hallifax, Geoff Warhurst. Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo.
Pharmaceutical research.
2004 May; 21(5):819-26. doi:
10.1023/b:pham.0000026434.82855.69. [PMID: 15180340] - R Belhoussine, H Morjani, J M Millot, S Sharonov, M Manfait. Confocal scanning microspectrofluorometry reveals specific anthracyline accumulation in cytoplasmic organelles of multidrug-resistant cancer cells.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
1998 Dec; 46(12):1369-76. doi:
10.1177/002215549804601205. [PMID: 9815278] - B Tranchand, G Catimel, C Lucas, M Sarkany, G Bastian, E Evene, J P Guastalla, S Négrier, P Rebattu, A Dumortier, M Foy, F Grossin, B Mazier, M Froudarakis, N Barbet, M Clavel, C Ardiet. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
Cancer chemotherapy and pharmacology.
1998; 41(4):281-91. doi:
10.1007/s002800050741. [PMID: 9488597] - C E Mackie, H E English, E Lelievre, B H Gordon, P Génissel, B V Robinson. Radioimmunoassay for the measurement of S9788 in serum and microdialysis samples.
Journal of pharmaceutical and biomedical analysis.
1997 Apr; 15(7):917-28. doi:
10.1016/s0731-7085(96)01924-3. [PMID: 9160258] - C J Punt, E E Voest, E Tueni, A T Van Oosterom, A Backx, P H De Mulder, B Hecquet, C Lucas, B Gerard, H Bleiberg. Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.
British journal of cancer.
1997; 76(10):1376-81. doi:
10.1038/bjc.1997.563. [PMID: 9374386] - A Demmer, T Dunn, T Hoof, P Kubesch, B Tümmler. Competitive inhibition of photoaffinity labelling of P-glycoprotein by anticancer drugs and modulators including S9788.
European journal of pharmacology.
1996 Nov; 315(3):339-43. doi:
10.1016/s0014-2999(96)00616-4. [PMID: 8982674] - S Urien, P Nguyen, G Bastian, C Lucas, J P Tillement. Binding of a new multidrug resistance modulator, S9788, to human plasma proteins and erythrocytes.
Investigational new drugs.
1995; 13(1):37-41. doi:
10.1007/bf02614218. [PMID: 7499106] - J Soudon, M Berlion, C Lucas, P Haddad, J P Bizzari, F Calvo. In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients.
Cancer chemotherapy and pharmacology.
1995; 36(3):195-203. doi:
10.1007/bf00685846. [PMID: 7781138] - S Oudard, N Thiounn, L Batel Copel, L Chauvenet, E Pujade Lauraine, A Bernadou. [Resistance to chemotherapy in cancers of the kidney and therapeutic perspectives].
Journal d'urologie.
1995; 101(3):122-4. doi:
NULL. [PMID: 8558029] - T Efferth, T A Dunn, M Berlion, H Langenbahn, E W Pommerenke, M Volm. Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S 9788.
Anticancer research.
1993 Jul; 13(4):905-8. doi:
NULL. [PMID: 8102519] - D M Bakes, N D Turner, B H Gordon, M P Hiley, B Walther, C Lucas. Method for the analysis of S9788, a drug to reverse resistance to anticancer agents, in animal plasma and human plasma and serum by high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography.
1993 May; 615(1):117-26. doi:
10.1016/0378-4347(93)80297-h. [PMID: 8340450] - S Léonce, A Pierré, M Anstett, V Pérez, A Genton, J P Bizzari, G Atassi. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance.
Biochemical pharmacology.
1992 Nov; 44(9):1707-15. doi:
10.1016/0006-2952(92)90063-o. [PMID: 1360210]